Phase 1 Study of CLR 125 in Triple Negative Breast Cancer

The goal of this clinical trial is to evaluate the safety and efficacy of 3 different dose levels of CLR 125 in patients with advanced triple negative breast cancer. The main questions the study aims to answer are: * What dose and regimen should be used in future trials of CLR 125 in patients with advanced triple negative breast cancer. * What side effects do participants have when taking CLR 125. Participants will: * Have CLR 125 administered via infusion 4 times each cycle; repeated every 8 weeks. * Visit the clinic once every 3 weeks for checkups and testing. * Report any side effects or

Trial Details

NCT ID
NCT07311993
Phase
PHASE1
Sponsor
Cellectar Biosciences, Inc.
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Iopofosine I 131
  • CLR 125
Locations (sample)
  • Jacksonville, Florida, United States|30.33218,-81.65565
  • Glen Burnie, Maryland, United States|39.16261,-76.62469
  • Rochester, Minnesota, United States|44.02163,-92.4699
  • Princeton, New Jersey, United States|40.34872,-74.65905

Key Eligibility Criteria

  • Unequivocal TNBC histology \[ER and PR less than 10% each and HER-2 negative\].
  • Patients that have progressed after at least one prior standard therapeutic regimen given alone or in combination (including, but not limited, to: …
  • Patients who have received neo-adjuvant or adjuvant therapy must be at least one year from that treatment regimen.
  • Patient is ≥ 18 years of age.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →